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1. Introduction
Inhaled therapy for medicinal purposes was used 
at least 4,000 years ago, but using antibiotics in a 
pulmonary dosage form takes back to 1948, when 
Abbot Laboratories developed the Aerohalor for 
the inhalation of Penicillin G powder [1]. However, 
large-scale therapeutic advancement dates back to 
1997, when tobramycin for inhalation was ap-
proved by the U.S. Food and Drug Administration 
(FDA) for use in patients with cystic fibrosis [2]. 
Respiratory tract infections affect people in all 
ages and are very common [3-5]. Globally, infec-
tions of the lower respiratory tract are among the 
top three major causes of morbidity and every 
year, these can be responsible for approximately 
3.5 million deaths in the world [6]. The most com-
mon treatment for respiratory infections involves 
the oral or parenteral administration of high doses 
of single or combined antibiotics, which can show 
undesirable side effects because of high systemic 
bioavailability [7, 8]. The ability to deliver thera-
peutic agents to the site of action may allow effi-
cient treatments of infectious diseases of the respi-
ratory tract and has many advantages over other 
routes [9]. 
The large surface area of the lungs is supplied 
by the excessive blood capillary network, which 
plays a role in the rapid absorption of the drug in 
the lungs. So the absorbed drug can directly reach 
the blood circulation, thus evading first pass me-
tabolism through this non-invasive drug delivery 
system [10, 11].
Therefore, the delivery of even low concentra-
tions of antibiotics to the lungs at the site of infec-
tion leads to much higher concentrations of antibi-
otics in the lungs, while reducing systemic expo-
sure and the risk of toxicity, and yielding thera-
peutic effects with smaller drug doses than the 
oral or parenteral route [12, 13].
One example is when an aminoglycoside antibi-
otic amikacin is given by IV administration, the 
drug concentration in the serum is three times 
higher than in the bronchial tissues, however, 
when amikacin is given by inhalation, drug con-
centration is 1000 times higher in the bronchial tis-
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sues than in the serum [14]. The other advantage 
of using a pulmonary dosage form of antibiotics in 
the treatment of chronic infections is that it is not 
associated with pain and it increases patient com-
fort and compliance, causing rational treatment 
outcome. Therefore, it enhances the quality of life, 
shortens the hospitalization period and significant-
ly decreases morbidity and mortality [15-18].
Currently, there are no drugs available that can 
stop the progression of Chronic Obstructive Pul-
monary Disease (COPD), but inhaled therapies 
have proved fruitful by preventing progression in 
many trials. Previously, many oral therapies were 
available for the treatment of idiopathic pulmo-
nary hypertension, however, new interventions 
are needed to increase patient compliance, which 
may affect disease progression. There has also 
been an increase in the development of aerosol-
ized liposomal formulations for the treatment of 
pulmonary neoplasia and 9-nitro-20(S)-camptoth-
ecin liposomal therapy has already been in clinical 
trials [19].
In spite of the great advantages of pulmonary 
dosage forms of antibiotics for the treatment of re-
spiratory infection, there are a few disadvantages 
for this route, which cause limitations when using 
antibiotics in a pulmonary dosage form [20]. Met-
abolic enzymes found in the lungs metabolize the 
antibiotics, however, the pathways and metabolic 
activities are different from degradation observed 
in the gastrointestinal tract [21]. Antibiotics can be 
cleared by the activity of alveolar macrophages 
found in the pulmonary alveoli, and the activity of 
these macrophages is relatively high since they 
are located at one of the extensive borders be-
tween the body and the outside environment [22, 
23]. On the other hand, the inhalation of antibiot-
ics may cause severe local irritation, wheezing, 
bronchospasm and coughing in patients [24].
In consideration of all these advantages and 
disadvantages, the development of inhaled antibi-
otics to treat lung infection is a largely active field, 
with four approved products in the USA and oth-
ers in the late stages of clinical progress [13].
In this review, we have discussed the pulmo-
nary dosage forms of antibiotics for the treatment 
of respiratory infections. Then particular inhaled 
formulations have been reviewed, highlighting 
fields where further research is required, e.g., par-
ticle engineering and particle preparation, and in-
novative formulations of pulmonary dosage 
forms. Then different methods of liposome prepa-
ration of antibiotics have been reviewed, and fi-
nally some of the formulations which contain a 
combination of antibiotics have been studied.
2. Inhaled antibiotic formulations in the market 
and in the development phase
2.1. Approved antibiotic formulations and their 
delivery routes 
The comparison of the general treatment guide-
line of respiratory tract infections and literature 
data about the pulmonary dosage form of antibi-
otics shows that these two lines are not parallel. 
The data show most research and investigations 
of pulmonary dosage forms of antibiotics focus 
on the treatment of cystic fibrosis rather than gen-
erally on the treatment of respiratory tract infec-
tion [25-27]. Cystic Fibrosis (CF) is an inherited 
disease caused by different mutations of the 
transmembrane conductance regulatory gene, 
and consequently respiratory failure follows after 
the chronic inflammation of the respiratory tract 
[28-30]. Currently, CF is the particular pulmonary 
infectious disease in which inhaled antibiotics 
have received FDA and European Medicines 
Agency (EMA) approval [24]. Future inhaled anti-
biotic trials have to focus on pulmonary diseases 
other than CF with large-scale manufacturing of 
marketed products for treating the variety of pul-
monary infections. Hence, the pulmonary dosage 
form of antibiotics can be used for the treatment 
of upper respiratory tract infections such as phar-
yngitis, tonsillitis, laryngitis, tracheitis, or lower 
respiratory tract infections like acute bronchitis 
and pneumonia often following after common 
cold and influenza [31-33]. Therefore, there will 
be a possibility for eradicating a broad spectrum 
of Gram-positive and Gram-negative bacteria 
from the respiratory system. The antibiotics dis-
cussed in this review have been a subject of re-
search and investigation over the years. Nowa-
days they are under clinical investigation or mar-
keting. Table I illustrates the groups of antibiotics 
in different dosage forms that are present in the 
market. So based on the data of table 1, we can as-
sume that many different oral and parenteral dos-
age forms of antibacterial agents have been for-
mulated; however, as Figure 1 shows, only 0.01% 
of antibiotic formulations exist in pulmonary 
dosage form and 0.04% of the total group of anti-
biotics involves inhaled formulations. Figure 2 
shows the ratio of different products in the USA 
and the UK. 
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Table I Summary of different key formulations of antibiotics in the USA and the UK/Europe. (Compiled from EMA’s 
website: www.ema.europa.eu, FDA’s database: www.fda.gov/home, National Institute of Pharmacy and food website:  
www.ogyei.gov.hu)
Group of Penicillins USA UK/Europe
Amoxicillin Capsule, Chewable tablet, Drops, 
Extended-release tablet, Tablet for 
suspension, Suspension
Oral hard Capsule, Dipersible tablet, Oral 
suspension, Powder for oral suspension, 
Powder for solution for injection and infu-
sion
Ampicillin Injection, Solution, Suspension, 
Powder for solution for injection, 
Capsules
Oral suspension, Powder for solution for in-
jection, Powder for oral suspension, Capsules
Dicloxacillin Capsule, Oral suspension
Carbenicillin indanyl Capsule Capsule
Nafcillin Injection, Infusion
Oxacillin Powder for injection, Infusion solu-
tion, Tablet
Capsule, Powder for solution for injection
Penicillin G Injection, Infusion, Tablet Injection, Infusion, Powder for injection, 
Tablet
Penicillin V Oral solution, Tablet Oral solution, Tablet
Piperacillin Injection, Infusion Injection, Infusion
Ticarcillin Infusion Infusion
Group of Cephalosporins USA UK/Europe
Cefaclor Capsule, Film coated tablet, Paede-
tric drops
Capsule, Suspension, Powder for suspension
Cefadroxil Capsule, Suspension, Tablet Capsule, Granule for oral suspension
Cefazolin Injection Powder for injection/ infusion
Cefdinir Suspension, Capsule
Cefepime Injection
Cefixime Tablets, Suspension Granules for oral suspension, Film coated 
tablets,  Powder for oral suspension
Cefotaxime Injection Powder for solution, Powder for injection or 
infusion
Cefotetan Injection
Cefoxitin Infusion
Cefprozil Suspension, Tablets
Ceftazidime Injection Powder for solution, Powder for injection or 
infusion
Ceftibuten Suspension
Ceftizoxime Injection Injection 
Ceftaroline Intravenous powder for injection Intravenous powder for injection
Ceftriaxone Injection Powder for solution, Powder for injection or 
infusion
Cefuroxime Injection, Infusion, Suspension, 
Tablet
Film-coated tablet, Suspension, Granules for 
suspension, Tablet, Powder for injection or 
infusion 
Cephalexin Capsule, Oral suspension, Tablet Capsule, Oral suspension, Tablet
Group of Carbapenems USA UK/Europe
Doripenem Injection
Ertapenem Injection Powder for concentrate for solution for infu-
sion
Imipenem For injection (combination with 
Cilastatin)
Powder for solution for infusion (combina-
tion with Cilastatin)
Meropenem Powder for injection/infusion Powder for solution for injection/infusion
Group of Monobactams USA UK/Europe
Aztreonam Inhalation, Injection, Infusion Injection 
Group of Tetracyclines USA UK/Europe
Demeclocycline Capsule, Tablet Capsule, Tablet
Doxycycline Capsule, Injection, Delayed release 
tablet, Subgingival controlled re-
lease gel
Capsule, Tablet
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Minocycline Extended release capsule, Extended 
release tablet, Injection, Sublingual, 
Oral microspheres 
Film-coated tablet, Tablet, Capsule
Tetracycline Tablet, Capsule, Suspension, Topi-
cal, Eye ointment
Capsule, Tablet, Eye ointment 
Group of Glycylcyclines USA UK/Europe
Tigecycline Injection Injection
Group of Aminoglycosides USA UK/Europe
Amikacin Injection Injection, Solution for infusion
Gentamicin Cream, Drops, Injection, Ointment, 
Solution, Topical
Drops, Infusion, Injection, Solution for injec-
tion
Neomycin Cream, Drops, Injection, Ointment, 
Solution
Tablet, Drops
Streptomycin Injection Injection
Tobramycin Eye drops, Injection, Inhalation 
solution, Ointment, Powder, Oph-
thalmic Solution
Injection, Infusion, Ointment, Eye drops
Group of Macrolides USA UK/Europe
Azithromycin Injection, Suspension, Tablet, Cap-
sule, Ophthamlic solution, Powder 
for suspension
Capsule, Film coated tablet, Injection, Sus-
pension, Powder for oral suspension, Powder 
for solution for injection
Clarithromycin Extended release tablet, Suspension Film coated tablet, Granules for Oral suspen-
sion, Powder for solution for infusion, Tablet
Erythromycin Capsule, Delayed release tablet, 
Delayed release Capsule, Drops, 
Gel, Infusion, Ointment, Oral sus-
pension, Solution, Infusion, Tablet, 
Topial pad  
Film coated tablet, Gastro-resistant tablet, 
Granules for oral suspension, Oral suspen-
sion, Powder for solution for infusion, Sugar 
free Oral suspension, Tablet
Telithromycin Tablet Film tablet
Group of Fluoroquinolones USA UK/Europe
Nalidixic acid Suspension, Tablet Tablet
Ciprofloxacin Drop, Extended release tablet, injec-
tion, Infusion, Ointment, Suspen-
sion, Solution, Tablet 
Drop, Film coated tablet, Granules for oral 
suspension, Solution for infusion, Tablet
Norfloxacin Drop, Suspension, Tablet Tablet
Ofloxacin Drop, Solution, Tablet Tablet
Levofloxacin Drop, Infusion, Injection concen-
trate, Oral solution, Solution, Tablet
Film-coated Tablet, Solution for infusion, 
Tablet
Moxifloxacin Eye drops, Injection, Tablet Film- coated tablet, Solution for infusion, 
Tablet, Eye drops, injection
Group of inhibitors of folate 
synthesis
USA UK/Europe
Mafenide Cream, Topical Solution Cream, Topical solution
Silver sulfadiazine Cream Cream
Sulfasalazine Delayed release tablet, Oral suspen-
sion, Rectal suspension
Enteric coated tablet, Gastro resistant tablet, 
Oral suspension, Tablet
Sulfisoxazole Suspension (combination with 
erythromycin)
                            
Groups of Inhibitors of 
folate reduction
USA UK/Europe
Pyrimethamine Tablet (combination with sulfadox-
ine)       
Tablet (combination with sulfadoxine)       
Trimethoprim Intravenous, Suspension Suspension, Tablet
Others USA UK/Europe
Chloramphenicol Capsule, Injection, Infusion Capsule, Drops, Ointment
Clindamycin Cream, Foam, Gel, Granules, Injec-
tion, Intravenous, Lotion, Solution, 
Suppository, Suspension, Swab 
Capsule, Cream, Hard capsule, Solution for 
injection, Solution for infusion
Linezolid Injection, Intravenous, Suspension, 
Tablet 
Film coated tablet, Granules for oral suspen-
sion, Solution for infusion
Quinupristin / Dalfopristin Powder for injection                       
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2.2. Approved inhaled antibiotic products 
2.2.1. Monobactams (Aztreonam)
β-lactam compounds are the first antibiotics to be 
discovered and widely used in many treatments. 
In this group, monobactams were developed with 
enhanced effect against aerobic Gram-negative 
bacteria. They are inactive against Gram-positive 
bacteria or anaerobic bacteria. They disrupt the 
bacterial cell wall [34]. The most common mono-
bactam antibiotic is aztreonam [35]. Since abso-
lute bioavailability is very low (about 1%) after 
oral administration, it is necessary for aztreonam 
to be administered intravenously or intramuscu-
larly [36]. This drug is very safe for treating pa-
tients who are allergic to penicillins and cephalo-
sporins [37]. Cayston®, aztreonam for inhalation 
solution, has been approved by FDA and EMA 
[38].
2.2.2. Fluoroquinolones (Ciprofloxacin, Levofloxacin)
Fluoroquinolones are potent antibacterial agents 
which target two enzymes, DNA gyrase and DNA 
topoisomerase IV [39]. Fluoroquinolones are rath-
er well-tolerated and safe antibiotics [40]. Cipro-
floxacin is the most potent fluoroquinolone for the 
treatment of pseudomonal infections associated 
with CF [41]. A liposomal ciprofloxacin formula-
tion for inhalation is currently in clinical trials for 
the treatment of respiratory diseases. Dry powder 
formulations of ciprofloxacin are in the advanced 
development stage [42]. Levofloxacin is an isomer 
of ofloxacin, which can be utilized in a wide range 
of infections due to its broad spectrum of activity 
[43]. Nebulized levofloxacin solution, Quinsair 
240 mg, is now in market [44, 45]. 
2.2.3. Aminoglycosides (Amikacin, Tobramycin)
Aminoglycosides are essential antibiotics in the 
treatment of severe and lethal infections [46]. 
Aminoglycosides exhibit bactericidal activity by 
inhibiting protein synthesis as they bind to the 
30S ribosomal subunit prior to ribosome forma-
tion, therefore causing the misreading of mRNA 
and leaving the bacterium unable to synthesize 
proteins necessary for bacterium growth [47]. Li-
posomal amikacin suspension (Arikayce) for in-
halation has been approved by FDA for the treat-
ment of respiratory diseases [48]. Tobramycin so-
lution (TOBI Novartis) has been approved in the 
USA and Europe. Dry powder inhalation tobra-
mycin (TOBI podhaler) has been approved in the 
USA and Europe [49]. Tobramycin exhibits irre-
versible ototoxicity or nephrotoxicity as side ef-
fects, however, when administered in a pulmo-
Figure 2 Ratio of different formulations in USA (left) and UK (right)
Figure 1 Ratio of the inhaled antibiotic Vs non-inhaled 
antibiotic formulation
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nary dosage form, it does not display these sys-
temic side effects, and it is an affirming study 
showing that systemic toxicity can be minimized 
via pulmonary dosage forms [50, 51].
2.2.4. Colistin
Colistin belongs to the polypeptide antibiotics 
known as polymyxins. Colistin is effective against 
most Gram-negative bacteria. Colistin can be giv-
en intravenously and resistance to colistin is rare 
[52]. Colistin is polycationic and has both hydro-
philic and lipophilic moieties [53]. Colistimethate 
sodium solution (Colomycin) has been approved 
in some European countries. Colistin methanesul-
fonate (Colobreathe) dry powder formulations 
have been approved in the USA and European 
countries. Zhou et al. reports a study which re-
veals that colistin in pulmonary dosage forms 
rarely results in systemic side effects [54-56].
2.2.5. Vancomycin
Vancomycin is a tricyclic glycopeptide antibiotic, a 
large hydrophilic molecule that poorly crosses the 
gastrointestinal mucosa. Vancomycin is effective 
against Gram-positive bacteria [57] and it has be-
come extremely useful because of its effectiveness 
against drug-resistant organisms [58]. Dry powder 
of vancomycin hydrochloride (AeroVanc) for inha-
lation has not been marketed yet but phase I clini-
cal study reported excellent tolerability of this an-
tibiotic in volunteers. So dry powder formulations 
of vancomycin are in the upgrading development 
stage [59].
3. Frequently used antibiotic formulation 
techniques 
There are numerous methods to produce pulmo-
nary drug delivery systems; however, here we 
tried to focus on methods that are mostly used for 
pulmonary dosage forms of antibiotics. 
3.1. Nebulization 
Nebulized antibiotics were used for the treatment 
of respiratory infection in the 1950s [60]. The neb-
ulization of antibiotics is a method for delivering 
therapeutic agents in a liquid form (solution or 
suspension) into the lungs by using nebulizing 
devices. Droplets with a diameter of approximate-
ly 1-5 µm are used for inhalation. This fraction 
can deposit in the large and small airways and the 
alveoli. Droplets larger than 5 µm deposit in the 
upper airways and droplets smaller than 1 µm are 
gradually exhaled again or may get into the sys-
temic absorption [61, 62]. As a routine rule, nebu-
lizers are suggested if the antibiotic cannot be ad-
ministered using other devices [63]. Nebulizers 
are usually used for patients who are critically ill 
or children not able to use handheld devices due 
to the smaller geometry of the respiratory tract as 
well as the lower inhalation flow rates [64]. Nebu-
lizers are also applied for any antibiotic available 
only in liquid form and not stable in any other 
form [65]. In the past, intravenous formulations 
were used to deliver antibiotics with different 
nebulizers for the treatment of serious respiratory 
infections. Intravenous formulations of antibiotics 
may contain additives and preservatives harmful 
to the lungs or not having appropriate osmolality, 
pH and particle size, which can cause airway irri-
tation, cough and bronchospasm [66]. During neb-
ulization, antibiotic liquid aerosols are generated 
by mechanical mechanisms like soft mist inhaler, 
human powered nebulizer or electrical mecha-
nisms such as vibrating mesh technology, jet neb-
ulizer and ultrasonic wave nebulizer [67]. Recent 
advances in nebulizer design have been reviewed 
elsewhere [68]. Conventional jet nebulizers gener-
ally have low drug delivery efficiencies and com-
pared to the other types of nebulizers, noisy 
working and heavy weight are the biggest draw-
backs of the jet nebulizer [69]. These issues have 
been improved by vibrating mesh nebulizers to 
produce aerosols with greater concentration of 
droplets and to reduce their administration time. 
As a consequence, minimal residual volume is ex-
hibited, which in turn yields lower antibiotic 
waste, rapid output and enhanced drug delivery 
efficiencies [70-73]. Pulmonary drug delivery by 
nebulization can also be optimized by digital soft-
ware regulation and performance feedback sys-
tems [74]. Table II enlists some antibiotics de-
signed by nebulization.
3.2. Dry Powder Inhalation
Regarding the possible dosage forms for the pul-
monary delivery of antibiotics, one can use a wide 
variety of formulations, such as dry powder inha-
lation (DPI). DPI formulations have been used for 
patient treatment for more than 60 years, but dur-
ing this period the fundamental formation of DPIs 
has not changed significantly [75, 76]. DPIs have 
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become the first choice of inhaled formulations in 
European countries. DPIs are formulations con-
taining micronized drug particles with an aerody-
namic particle size of less than 5 µm [77]. For ade-
quate deposition to reach the central and alveolar 
parts of the lungs, the optimal size of particles 
should be in the region of 1-5 µm. The most im-
portant approach in designing DPIs is that the 
time required for delivering each dose is short 
and even less than one-third of the time is needed 
for delivering the same dose for nebulization. This 
fact is expected to improve patients’ adherence 
[78, 79]. DPIs of antibiotics are more stable, offer 
ease of administration and have less risk of micro-
bial contamination than parallel liquid formula-
tions [80-82]. DPIs have conventional application 
as a formulation of micronized drug in a carrier-
based system [83]. Because the small particles 
(1-5µm) tend to stick with each other due to high 
surface free energy, carriers such as lactose, man-
nitol and trehalose are used for preventing the ag-
glomeration of particles. These excipients reduce 
the surface energy, overcome cohesive forces and 
adhesive forces, and limit the flowability of API 
particles [83]. That is why the carrier-based system 
is being explored for surface modification and ac-
tive targeting. By an appropriate use of the poly-
mer or lipid carrier, the pulmonary drug delivery 
approach can result in interesting outcomes.
Lactose is the most typical and frequently used 
carrier in DPIs but because of clinical issues, lac-
tose cannot be used for drug delivery to diabetic 
patients and people with lactose intolerance [84-
87]. Mannitol, a hexahydric alcohol, has been fre-
quently used as a carrier for aerosol drug delivery 
[17]. Mannitol is less hygroscopic than lactose 
and gives a suitable sweet aftertaste, which is a 
benefit over lactose and enhances the compliance 
of patients [88]. A therapeutic DPI aerosol for the 
treatment of CF and chronic bronchitis (Bronchi-
tolTM), approved by the FDA and the EMA, con-
tains mannitol as a carrier system [89]. A DPI for-
mulation for the inhalation of ciprofloxacin hy-
drochloride was prepared with different percent-
ages of mannitol as a combination formulation. 
Mannitol improved mucous clearance in the re-
spiratory tract while concurrently treating local 
chronic infection, chronic obstructive pulmonary 
disease and cystic fibrosis [90]. Trehalose dihy-
drate is a disaccharide non-reducing sugar and 
can be used as another carrier. A DPI of trehalose 
microparticles with low water content was suc-
cessfully produced by the spray-drying technique 
[91]. Although trehalose leads to autophagy and 
can be used for the treatment of Huntington’s dis-
ease, Parkinson’s disease or tauopathies, it does 
not exhibit any benefit for the treatment of infec-
tions [92]. Moreover, DPIs of antibiotics usually 
have large therapeutic doses (e.g. between 10 mg 
and 100 mg of antibiotics), thus the carrier causes 
difficulty in the application of the DPI due to the 
increased powder volume and the scaled-down 
use of antibiotics via pulmonary dosage forms 
[93]. For about the last two decades, there has 
been significant research on the design of carrier-
free systems for DPIs [83]. Applying a carrier-free 
system makes the delivery of a high dose of anti-
biotics to the lungs possible by limiting the 
amount of excipient [94]. Carrier-free formula-
tions can be handled by coating particles with lip-
ids, amino acids and polymers by the mechanofu-
sion dry coating process [95,–98]. The drug depo-
sition of DPI in the lungs is essentially controlled 
by its aerodynamic behavior. Currently, the aero-
dynamic properties of DPIs are being improved 
by changing formulation strategy and particle en-
gineering [99]. These strategies are discussed in 
detail in Section 3.3.
Table II Nebulized antibiotics and their clinical impact
Therapeutic agent Method Characteristic excipi-
ent
Clinical/Biopharmaceutical impact
Ciprofloxacin Liposome formula-
tion by membrane 
extrusion method
Hydrogenated soy 
phosphatidylcholine/
cholesterol
Enhanced drug encapsulation/size/
stable release [75].
Ciprofloxacin Liposome formula-
tion by membrane 
extrusion
Polysorbate 20/hydro-
genated soy phosphati-
dylcholine/cholesterol
Enhanced release rate [76].
Ciprofloxacin Liposome formula-
tion by thin film 
method
(DOTAP)*/ (DOPE)** 
(PC)***/ cholesterol
Decreased MICs [77].
Colistin Dry film method Dioleoyl-phosphatidyl-
choline
Enhanced release rate [78].
*1,2-Dioleoyloxy-3-trimethylammonium-propane **1,2-dioleoyl-sn-glycero-3-phosphoethanolamine *** phosphatidylcholine
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3.3. Preparation methods for DPIs
3.3.1. Milling (top down)
Milling involves the breakdown of coarse large par-
ticles into fine particles by the use of mechanical 
force. Wet milling and dry milling are the common 
methods used in the production of pharmaceutical 
products. As the name indicates, wet milling in-
volves the breakdown of large particles while they 
remain suspended in liquid medium. Dry milling 
may be sub-branched into various other forms of 
milling that do not require moisture content during 
the breakdown. Wet milling is often used for drugs 
which have a high residual moisture content [100]. 
The pharmaceutical industry also uses jet milling, 
also referred to as fluid energy milling, for most of 
the pharmaceutical dosage form designs. Jet-milled 
powders are highly cohesive because of the high 
surface energies of the particles. This problem can 
be resolved by adding excipients and carriers. How-
ever, this approach seems unfavourable for high-
dose antibiotics. The great advantage of this meth-
od is that it does not require separation [101-103]. 
The process of milling can lead to a decrease in the 
particle size and moderately reduced crystallinity 
because of the production of amorphous form [104]. 
So particle engineering is a very important key fac-
tor for the production of carrier-free (or with mini-
mum carrier) inhalable powders of antibiotics with 
good aerosolization behavior [105, 106]. Overall, the 
process of milling improves drug dissolution and 
solubility profiles. 
3.3.2. Solvent evaporation method (bottom up)
The other process used commonly is the solvent 
evaporation method. It includes spray-drying, 
freeze-drying, spray freeze-drying, and supercrit-
ical fluid followed by rapid expansion. Spray-dry-
ing is a single-step particle formation process and 
is an appropriate way for particle engineering un-
der a controlled manner for scale-up in industry. 
It is used for the production of dry powder from a 
solution, suspension and emulsion by rapid dry-
ing in the presence of a hot gas [107]. Amorphous 
and crystalline materials may be yielded by spray-
drying depending on feedstock. This method 
gives better control over the particle size and 
shape, yielding powders with a narrow particle 
distribution and low particle surface energy. Fur-
thermore, it creates possibility for the addition of 
excipients to promote the dispersibility of the 
powder, to enhance the stability of the formula-
tion, to improve cellular uptake and to complete a 
formulation with modified drug release. Carrier-
free DPI formulations of ciprofloxacin nanoplex 
were developed by spray-drying and spray freeze-
drying methods. D-Mannitol and L-leucine were 
used as drying adjuvant and aerosol dispersion 
enhancer, respectively. Another example is the 
manufacturing of inhaled tobramycin (TOBI® 
podhaler®, Novartis) [108-110]. PulmoSphere of to-
bramycin can also be prepared by treating an 
emulsion under high-pressure homogenisation 
followed by spray-drying.
Different excipients have different effects on the 
mass, particle size, particle morphology and aero-
dynamic behavior of microparticles [111]. A man-
nitol–leucine combination resulted in better aero-
solization behavior of the therapeutic agent, but 
mannitol exhibited some degree of recrystalliza-
tion. A trehalose–leucine combination shows good 
potential to be used as excipient for the pulmo-
nary delivery of potent antibiotics [109]. Although 
spray-drying is a conventional method to produce 
DPIs, the exposure of heat-sensitive antibiotics, 
e.g. penicillin, to the high temperature of the spray 
dryer (>100℃) is not appropriate. The nano spray 
dryer provides very adequate results for the for-
mulation of heat-sensitive materials in submicron 
particles, with high yields (70% to 90%) related to 
the conventional spray-drying method [112]. 
Freeze-drying works by freezing the therapeutic 
agent and then decreasing the pressure to allow 
the frozen water in the material to sublimate di-
rectly from the solid phase to the gas phase [113]. 
Freeze-drying has been considered as a good tech-
nique to enhance the long-term stability of the mi-
croparticles and nanoparticles of antibiotics [114].
The worldwide rise in mortality rates because 
of antibiotic resistance turned out to be the tough-
est challenge to modern medicine and therapeutic 
agents [115]. Monotherapy with a single antibiotic 
may lead to the development of antibiotic resis-
tance due to newly discovered pathogens, which 
cause resistance to a broad spectrum of antibiotics 
[116]. Hence, combination therapies, containing 
different types of antibiotics, have been intro-
duced to inhibit the development of drug resis-
tance [117]. Antibiotic combinations should be ac-
cording to the synergistic effect of antibiotics and 
should avoid interaction [118]. Cospray-drying is 
the method which can assist in such combination 
therapy to achieve the desired effect. The cospray-
dried combination of ciprofloxacin and doxycy-
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cline hydrochloride (1:1) is suitable for inhalation 
and highly effective against Staphylococcus aureus, 
P. aeruginosa and Streptococcus pyogenes [119]. A 
formulation consisting of highly porous nanopar-
ticles loaded with tobramycin surrounded by a 
matrix composed of amorphous clarithromycin, 
with a median particle size of about 400 nm, was 
synthesized by high-pressure homogenisation. In-
terestingly, the results showed that the formula-
tion of the combination of two antibiotics en-
hanced powder dispersion during inhalation. Lo-
cal drug deposition profiles were almost similar 
for the antibiotics and reached the target site con-
currently. The dissolution rate revealed that tobra-
mycin and clarithromycin dissolve with ease in 
the lungs [93]. A formulation comprising cipro-
floxacin hydrochloride and gatifloxacin (fourth 
generation of fluoroquinolone), prepared by the 
spray-drying method, showed a synergistic anti-
microbial effect in the lungs [120]. 
4. Novel DPI formulation strategies and carriers 
for inhaled antibiotics
4.1. Preformulation and Quality by Design approach
The majority of research and innovation for pul-
monary dosage forms of antibiotics does not 
achieve scale-up and marketing. The main rea-
sons are the lack of feasible process, the inappro-
priate way for the efficient and effective control of 
changes, the inability to achieve reasonable prod-
uct quality, the high cost with a low yield, the in-
ability to predict effects of scale-up on the final 
product, the inability to analyze or understand 
reasons for manufacturing failures, and the large 
number of batch failure. Hence, Quality by Design 
(QbD) is necessary before every laboratory re-
search, new formulation, particle engineering and 
powder formulation [121-124]. 
The pharmaceutical QbD is a systematic path-
way for the development of a new formulation, 
which begins with a predefined formulation and 
indicates product and process understanding and 
process control, based on quality risk manage-
ment [125]. QbD appears to enhance the assurance 
of safe and effective drug supply to the patients, 
and also attempts to significantly improve manu-
facturing quality administration. QbD principles 
have been used to regulate product and process 
quality in industry and have been approved by 
the FDA for the discovery, formulation and devel-
opment of drugs [126]. Table III identifies some of 
the characteristic differences between convention-
al and experimental design QBD approaches.
So QbD ensures better design of products with 
fewer problems in manufacturing and allows for 
the better understanding of how APIs and excipi-
ents affect manufacturing. It also leads to a reduc-
tion in the overall costs of manufacturing, thus 
speeding up  the process of approvals and acceler-
ating scale-up production [127]. The specific de-
sign of the inhaler is very critical in achieving ac-
ceptable airflow to deposit the drug into the thera-
peutically effective region of the lungs [128]. DPI 
dosage form properties can be controlled by ad-
justing the particle size, size distribution, particle 
density, particle morphology and shape [129-131]. 
The Ishikawa diagram in Figure 3 illustrates the 
parameters influencing the quality of DPI prod-
ucts in general, assembling all the influencing pa-
rameters of the aimed DPI product [97].
An amikacin product for inhalation in CF pa-
tients was manufactured by spray-drying the pure 
drug, and the formulation exhibited great respira-
bility and flowability. An experimental design was 
applied on the process in relation to six Critical 
Quality Attributes (CQAs) of the finished product 
and five Critical Process Parameters (CPPs). The 
application of the experimental design was set up 
to achieve amikacin powders with both emitted 
dose (ED) and fine particle dose (FPD), completely 
with high regulatory and scientific references  [132]. 
The dry powder formulations of ciprofloxacin 
hydrochloride were prepared by the spray-drying 
method following the QbD approach. An ad-
vanced quality management method was used to 
predict the final quality of the product in relation 
to the QbD-based theoretical preparatory parame-
ters. Dry powder inhalation formulation tests 
Table III  Differences between conventional and QBD approaches
Characteristic Conventional QbD
Pharmaceutical development Univariate experiments Multivariate experiments
Manufacturing process Fixed Flexible
Process control and control strategy Slow and by initial intermediate 
and end product testing 
Actual time, risk-based controls shifted 
upstream  
Product designation It is based on batch data based on desired product achievement 
(safety and efficacy)
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were then successfully performed in practice 
[133].
4.2. Novel formulations and carriers for antibiotics
4.2.1. Microparticles
DPI formulations are usually comprised of mi-
cronized drug powder. One of the highest signifi-
cant upgradations, in powder technologies from 
the micronization of large drug crystals into a re-
spirable range for use in DPIs, is enhancing their 
dispersibility by the reduction of interior adhesive 
forces in the crystals [105]. Pharmaceutical indus-
tries have high demand for crystalline pharma-
cons. Most products for pulmonary dosage forms 
in the market are being manufactured in the crys-
talline state.
Crystalline drugs exhibit more stability; and for 
formulation development, thermodynamically 
stable polymorphs are selected. Salts are selected 
for their better solubility, purity and crystallinity 
relative to the neutral form [134]. For example, a 
DPI formulation was prepared with the sonicated 
solution of ciprofloxacin in acetone because of the 
very low solubility of neutral ciprofloxacin. In 
this formulation, L-leucine was used as a charac-
teristic excipient [135]. In another DPI formula-
tion, ciprofloxacin hydrochloride was used and 
the formulation preparation did not require a tox-
ic organic solvent and a complicated method due 
to the high solubility of the salt form in water. A 
great advantage of the second formulation is that 
L-leucine can dissolve in water easily, too. In both 
cases the DPI showed excellent aerodynamic be-
havior with a fine particle fraction (FPF) value of 
more than 80% [133].
The conventional method of drug powder for-
mulation in the microsized range involves crystal-
lization followed by milling to reduce the particle 
size and to attain the suitable size. This method is 
not an appropriate method as it implies incom-
plete control over the particle size, size distribu-
tion, particle morphology and crystallinity. Muco-
adhesive microparticles are able to swell and hy-
drate after deposition in the lung epithelial cells 
[136, 137]. The encapsulation of ciprofloxacin in 
chitosan is one such example, as the polymer has 
Figure 3 Ishikawa diagram for DPI formulation in general
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swelling properties along with biodegradability 
and biocompatibility characteristics, and antibac-
terial and anti-inflammatory properties. Addition-
ally, these swelling microparticles possess bioad-
hesive properties, promoting adhesion to the pul-
monary system and enhancing antibacterial effect 
[136, 138].
For the microparticles to maintain sustained lo-
cal antibacterial effect, they should avoid phago-
cytosis by alveolar macrophages. The particle size 
range that is optimal for pulmonary inhalation 
(1–5 µm) is also optimal for phagocytosis [139, 
140]. Large porous microparticles, with low densi-
ty but large geometric diameters, display ideal 
lung deposition profiles and can overcome phago-
cytosis challenges [141-143]. Spray-drying is gen-
erally used with different excipients like dipalmi-
toyl-phosphatidylcholine (DPPC) and albumin to 
produce large porous microparticles [144, 145]. 
Also, large porous microparticles can be produced 
by treating solid microparticles with supercritical 
CO2 [146, 147]. Another interesting method for the 
production of large porous microparticles is the 
application of ammonium bicarbonate as an effer-
vescent porogen, which decomposes into ammo-
nia and carbon dioxide in an acidic aqueous solu-
tion or at high temperature  [148].
Porous particles of tobramycin and ciprofloxa-
cin produced by the emulsion method followed 
by spray-drying exhibited enhanced and satisfy-
ing flowability and aerosolization performance 
[149, 150]. A simple double-emulsion method us-
ing poly(DL-lactide-co-glycolide) polymer result-
ed in large porous biodegradable microspheres of 
capreomycin for pulmonary drug delivery. The 
morphology of particles displayed a highly po-
rous interior and an outer rough surface [151].
4.2.2 Nanoparticles
Nowadays, nanoparticles are being widely inves-
tigated for antibiotic inhalation therapy [152], 
however, the formulation of nanoparticles for 
drug delivery application came to the fore in the 
1960s [153]. The considerable advantage of 
nanoparticle formulations is that they  improve 
the solubility and dissolution rate of water-insolu-
ble antibiotics [154]. As an example, the nanoparti-
cles of ciprofloxacin exhibited a speedy dissolu-
tion profile compared to the supplied ciprofloxa-
cin powder. Besides, this formulation of nanopar-
ticles of antibiotics enhanced the Minimum Inhib-
itory Concentration (MIC) and antibacterial 
activity. It was also observed that amikacin 
nanoparticles exhibit MIC and a bacteriostatic ef-
fect against P. aeruginosa compared to less than 
half of the values for free amikacin [155, 156]. Due 
to their small size and large surface area, the 
nanoparticles of the antibiotic showed significant 
and enhanced aerodynamic behaviour. An exam-
ple of tobramycin nanoparticles can be noted 
where the formulation exhibited an FPF of 61% 
compared to the microparticles of tobramycin 
with an FPF of 36% [157].
On the other hand, nanoparticles act as foreign 
materials, with special physiochemical properties, 
in human bodies and are recorded to have severe 
adverse effects on the lungs, like inflammation, fi-
brosis and mutations along with oxidative stress. 
Further, these damages could cause pulmonary 
diseases and diseases in the other parts of body 
[158]. Inhaled nanoparticles can be exhaled be-
cause of their extremely low mass. These prob-
lems have been rectified by formulating nanopar-
ticles into inhalable microparticles into a matrix or 
carrier system. These matrices can be synthetic 
polymers such as PVA, PVP and PLGA; amino ac-
ids like L-leucine; or polysaccharides such as chi-
tosan and sodium hyaluronate [159-161].
4.2.3. Solid lipid microparticles and solid lipid 
nanoparticles
The incorporation of lipid into formulations 
brought about the development of porous parti-
cles with low density [162, 163]. There are various 
methods which have been reported for the syn-
thesis of solid lipid microparticles (SLM) and solid 
lipid nanoparticles (SLN) [164]. Some of these 
methods are double emulsion solvent evaporation 
with freeze-drying [165], high pressure homoge-
nization followed by spray-drying [166-168], melt 
emulsification followed by spray-drying [169], 
melt emulsification followed by freeze-drying 
[170, 171] and simple spray-drying [144]. SLNs usu-
ally have a spherical shape consisting of a solid 
lipid bulk stabilized by a surfactant. Biological 
membrane lipids such as phospholipids, and ste-
rols (cholesterol) can be applied as stabilizers [172]. 
The most important advantages of SLNs from the 
pulmonary perspective include the possibility of 
large-scale production and ability of the incorpo-
ration of lipophilic and hydrophilic drugs, lack of 
biotoxicity of the carrier, high loading capacity, 
drug target delivery and controlling drug release 
[173].
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4.2.4. Liposomes
Discovered by Dr. Alec Bangham in 1961 [174], li-
posomes seem to be a relevant and useful choice 
for pulmonary drug delivery considering their 
preparation from components compatible with the 
lungs, with a good safety profile. Arikayce is the 
first liposomal preparation clinically approved for 
pulmonary administration. No marketed inhaled 
liposomal antibiotic preparation was available 
previously [175]. Liposomal formulations of in-
haled antibiotics are considered to be sustained 
drug delivery systems due to their low and slow 
solubility. These formulations prolong the action 
of drug in the infectious part and increase the an-
tibacterial effect. On the other hand, the sustained 
release of antibiotics minimizes dosing frequency 
and thereby enhances patient compliance. Liposo-
mal antibiotics  can also act as targeted drug de-
livery systems [176]. The encapsulation of drugs in 
liposomes also reduces the occurrence of local ir-
ritation as that caused by traditional pulmonary 
dosage forms. Overall, these benefits of liposomal 
formulations make them an appropriate drug de-
livery system for antibiotics. The surface-mannose 
modification of liposomes with mannose pro-
motes the active targeting of macrophages with 
mannose receptors and provides efficient aerosol-
ized liposomal delivery [177].  Liposome formula-
tions can be administered in a liquid dosage form, 
e.g. nebulizer. However, some solid preparations 
prepared by spray-drying or spray freeze-drying 
can be designed as DPIs [178].
Liposomes are formed immediately when lipids 
are hydrated in contact with water and then dried 
afterwards to form spheres.  Generally, in a large 
scale-up process, lipids are first dissolved in an 
appropriate solvent (mixture of water, ethanol 
and the other organic solvent in a different ratio) 
and then rotatory evaporation removes the sol-
vent. A thin layer of lipid film is formed on the 
wall usually in multilamellar vehicles (MLVs) 
[179-181]. Another method is the ethanol injection 
method, in which liposomes are formed after the 
Table IV Different DPI formulations with their therapeutic outcome
Therapeutic 
agent
Method Characteristic Ex-
cipient
Particle size Resulting therapeutic out-
come
Ciprofloxacin 
and
doxycycline
Spray-drying method PVA* Microparticle Controlled release antibiotics 
[94].
Levofloxacin Nanoprecipitation/emulsi-
fication–solvent evapora-
tion methods
PLGA**/PCL*** Nanoparticle Improved antibacterial effi-
cacy [188].
Levofloxacin Emulsification–solvent 
evaporation  method
PLGA**/phosphati-
dylcholine
Nanoparticle Improved antibacterial effi-
cacy [189].
Tobramycin Emulsion/solvent diffu-
sion method
PLGA**/PVA*/
chitosan/alginate/
lactose
Nanoparticle Increased encapsulation effi-
ciency/release rate/lung depo-
sition pattern [190].
Amikacin Solid-lipid coated by sol-
vent diffusion method/
freeze-drying
Sucrose/
Dextrose/Mannitol
Nanoparticle Long-release term/antibacte-
rial efficacy [159] [160].
Ciprofloxacin Sonicating/freeze-drying L-Leucine Nanoparticle Increased the dissolution rate/
improved aerodynamic prop-
erties [139].
Ciprofloxacin 
hydrochloride
Spray-drying L-Leucine/PVA*/
Cyclodextrin
Microparticle Enhanced the aerodynamic 
behaviour [137].
Tobramycin High-pressure homogeni-
sation/spray-drying
Sodium
glycocholate
Mixture of 
micro- and 
nanoparticles
Enhanced lung deposition 
[161].
Ciprofloxacin Self-assembly method Chitosan/PEG Loaded 
nanoparticle in 
micro hydrogel 
particles
Suitable aerodynamic charac-
teristics/sustains drug release 
[140].
Ciprofloxacin Emulsion/spray-drying _____ Microparticle Enhanced tolerability assess-
ments [153].
Ciprofloxacin Anti-solvent precipitation 
method/spray-drying
_____ Microparticle Enhanced aerosol perfor-
mance [191].
*Poly-vinyl alcohol **poly(lactic-co-glycolic acid) ***Polycaprolactone
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injection of the organic phase into the aqueous 
phase and then by applying diafiltration or ultra-
filtration to remove the excess solvent [182, 183]. 
The possibility of encapsulating hydrophilic and 
lipophilic drugs and easy scale-up are major mer-
its of this method.
A few DPI formulations with their therapeutic 
outcomes are mentioned in Table IV.
5. Patient History
The efficacy and tolerability of nebulized antibiot-
ics in trials remain low and only involve a single 
center or are confounded by inadequate patient 
enrollment, poor methodology, failures in stan-
dardizing or reporting delivery methods, and par-
ticle sizes. Different studies have used different 
doses or formulations as well as differing patient 
cohorts. Hence, there is no standardized tech-
nique for the administration of a given aerosol-
ized drug. These factors make the comparison of 
efficiency and tolerability difficult and pose chal-
lenges when trying to standardize this method of 
treatment and in establishing best practice [184]. 
Studies of inhaled antibiotics targeting non-CF 
pathogens for suppression, eradication or prophy-
laxis are scarce [75], and no inhaled antibiotics are 
approved for lungs in non-CF infections, includ-
ing COPD, melioidosis, pneumonic plague, an-
thrax, Q fever, tularemia, and for patients with 
other infections, including non-tuberculous myco-
bacteria. Despite the need, limited ongoing stud-
ies are observed for the dry powder form of van-
comycin assessing the efficacy and safety of sup-
pressive therapy for methicillin-resistant Staphy-
lococcus aureus (MRSA) infection. The only rec-
ommended prophylactic strategy available is the 
chronic prophylaxis to prevent the acquisition of 
S. aureus, which is used primarily in the UK [185].
6. Future perspective and conclusion
Inhalable powders in the form of nanoparticles 
have potential as a treatment option of respiratory 
tract infections. Targeted delivery is possible by the 
optimization of formulation parameters, and new 
nanoparticle formulation strategies that may en-
hance safety, stability, dispersion and deposition. 
Liposomal formulations of inhaled antibiotics 
are advanced drug delivery systems designed for 
sustained drug release and targeted drug delivery 
to the lungs; nevertheless, low stability and diffi-
culty in liposomal DPI production are notable is-
sues. In this field new techniques and strategies 
are necessarily required to overcome the challenge 
of instability of most liposome formulations. 
In the development of combination therapy, it 
is possible to create novel technological methods 
to design a combination of antibiotics in which 
each particle can have several layers made of dif-
ferent antibiotics with different bactericidal activi-
ties. In this way, resistance by bacteria can be re-
duced, and therefore a new dimension to antibiot-
ic treatment can be explored. 
Inhaled antibiotics for the treatment of respira-
tory tract infections have a great and long history; 
however, these therapies focus on CF patients. 
Right now, there is no academic indication for us-
ing inhaled antibiotics for the treatment of non-CF 
patients. Hence, prescriptions for patients with 
non-CF respiratory infection will continue to be 
based on oral or parenteral dosage forms until sci-
entific evidence from progressing clinical trials be-
come available. Literature data concerning non-
cystic fibrosis patients in the next years will ex-
plain much. Pulmonary dosage forms of antibiot-
ics show interesting results due to high drug con-
centrations in the respiratory tract with minimum 
systemic drug exposure. However, the formula-
tion of antibiotics for pulmonary dosage forms is 
relatively complicated. Antibiotics are adminis-
tered in higher doses than the other therapeutic 
agents for asthma or other inflammatory diseases. 
DPIs have also been favored in recent years for the 
delivery of inhaled antibiotics. The particle engi-
neering technique is a key factor to improve inhal-
able formulations that are able to deliver the drug 
with advanced therapeutic effect. Advanced parti-
cle engineering techniques are also being em-
ployed to revise the manufacturing of DPI formu-
lation for delivering antibiotics. Pulmonary deliv-
ery systems for the treatment of viral lung infec-
tions are completely absent, and this area should 
be explored to develop potent antiviral therapies. 
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